76 Chapter 4 Table 3. Characteristics of the study population. Variables (n = 87) Gender, n (%) Male 44 (50.6) Female 43 (49.4) Ethnicity, n (%) White 66 (75.9) Other 21 (24.1) Gestational age (weeks), mean (SD) 29.0 (1.8) Extremely preterm, n (%) 25 (28.7) Very preterm, n (%) 62 (71.3) Birthweight (g), mean (SD) 1210 (216) Birthweight SDS, mean (SD) 0.0 (0.7) Birthweight SDS <−1.3, n (%) 3 (3.4) BPD, n (%) 30 (34.5) NEC, n (%) 8 (9.2) LOS, n (%) 30 (34.5) PDA, n (%) Hemodynamically Insignificant PDA 11 (12.6) Hemodynamically Significant PDA 8 (9.2) ROP, n (%) ROP stage I 4 (4.6) ROP stage III 1 (1.1) IVH, n (%) IVH grade I 8 (9.2) IVH grade II 11 (12.6) IVH grade III 4 (4.6) BPD: Bronchopulmonary dysplasia, IVH: intraventricular hemorrhage, LOS: Late-onset sepsis; NEC: Necrotizing enterocolitis; PDA: patent ductus arteriosus, ROP: retinopathy of prematurity. Changes in IGF-1 During Hospitalisation Between birth and the second week of life, IGF-1 levels dropped from 4.8 nmol/L to 3.2 nmol/L in extremely preterm infants (mean decrease −1.5, 95% CI −5.2–2.2, p = 0.314). In very preterm infants, IGF-1 showed a mean decrease of 0.3 nmol/L (95% CI −2.1–1.4, p = 0.675) between birth and the second week of life. From the second week of life, IGF-1 showed a mean (SD) increase of 0.6 (0.2) nmol/L per week in very preterm infants and 0.7 (0.1) nmol/L per week in extremely preterm infants (mean difference 0.1, 95% CI 0.0–0.2, p = 0.143) (Figure 2).
RkJQdWJsaXNoZXIy MTk4NDMw